1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. Company
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
Delayed London Stock Exchange  -  11:38 2022-07-05 am EDT
10764.00 GBX   -0.41%
01:00pEuropean Bourses Hammered by Recession Fears; Euro Falls to 20-Year Low
MT
11:46aGLOBAL MARKETS LIVE : J Sainsbury, Foxconn, JPMorgan, Comcast, Tesla...
09:51aASTRAZENECA : Buy rating from Deutsche Bank
MD
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo AstraZeneca PLC
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:

- product sales (97.7%). Net sales break down by treatment area between oncology (35.7%), cardiovascular, renal and metabolic diseases (21.9%), respiratory and autoimmune diseases (16.5%), and other (25.9%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);

- collaboration revenue (2.3%).

Net sales are distributed geographically as follows: the United Kingdom (8.7%), Continental Europe (20.9%), Americas (37.5%) and Africa/Asia/Australia (32.9%).

Number of employees : 83 100 people.
Sales per Business
20202021Delta
Oncology8 461.0040.8%9 487.3634.9% +12.13%
Cardiovascular, Renal & Metabolism5 533.5726.7%5 831.4421.4% +5.38%
Respiratory & Immunology4 177.4720.1%4 387.3916.1% +5.03%
COVID-19--2 909.9010.7%-
Rare Disease--2 232.238.2%-
Other Medicines2 017.389.7%1 721.076.3% -14.69%
Collaboration566.932.7%636.952.3% +12.35%
GBP in Million
Sales per region
20202021Delta
United States6 983.2533.6%8 759.5232.2% +25.44%
China4 168.1120.1%4 364.1316% +4.7%
Japan2 001.799.6%2 468.559.1% +23.32%
United Kingdom1 357.666.5%2 359.488.7% +73.79%
Other Asia, Africa and Australasia1 196.245.8%1 729.806.4% +44.6%
Sweden800.093.9%1 688.356.2% +111.02%
Other Rest of Europe1 084.725.2%1 417.145.2% +30.65%
Germany730.693.5%1 080.494% +47.87%
Other Americas593.442.9%874.723.2% +47.4%
France509.222.5%665.312.4% +30.65%
Canada464.772.2%561.332.1% +20.78%
Spain310.371.5%420.271.5% +35.41%
Italy336.101.6%419.541.5% +24.83%
Australia219.911.1%397.731.5% +80.86%
GBP in Million
Managers
Name Title Age Since
Pascal Soriot Chief Executive Officer & Executive Director 62 2012
Aradhana Sarin Chief Financial Officer & Executive Director 47 2021
Menelas Pangalos EVP-Biopharmaceuticals Research & Development 54 2019
Pam Cheng Executive VP-Operations & Information Technology 50 2015
Henry Cremisi Medical Director - -
Regina Danielson SVP, Head-Research & Early Development - -
Katarina Ageborg Chief Compliance Officer & EVP-Sustainability - 2017
Jonathan Thomas Charles Slade Group Treasurer 56 -
Adrian Charles Noel Kemp Secretary 55 2009
Ruud Dobber, Dr. Executive VP-Biopharmaceuticals Business - 2019
Members of the board
Name Title Age Since
Leif Johansson Non-Executive Chairman 69 2012
Marcus Wallenberg Independent Non-Executive Director 65 1999
Philip Arthur John Broadley Senior Independent Non-Executive Director 60 2021
Nazneen Rahman, Dr. Independent Non-Executive Director - 2017
Sherilyn McCoy Independent Non-Executive Director 62 2017
Deborah DiSanzo Independent Non-Executive Director 61 2017
Tony Mok, Dr. Independent Non-Executive Director 60 2019
Michel Demaré Independent Non-Executive Director 65 2019
Pascal Soriot Chief Executive Officer & Executive Director 62 2012
Euan A. Ashley, Dr. Non-Executive Director - 2020
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 1,549,470,612 1,493,390,307 96.4% 0 0.0% 96.4%
Shareholders
NameEquities%
Wellington Management Co. LLP 64,146,178 4.14%
BlackRock Investment Management (UK) Ltd. 54,582,684 3.52%
Investor AB (Investment Company) 51,587,810 3.33%
The Vanguard Group, Inc. 48,087,000 3.10%
Capital Research & Management Co. (World Investors) 46,132,337 2.98%
Norges Bank Investment Management 30,519,000 1.97%
BlackRock Fund Advisors 27,379,431 1.77%
BlackRock Advisors (UK) Ltd. 21,537,049 1.39%
GQG Partners LLC 15,357,000 0.99%
SSgA Funds Management, Inc. 13,546,000 0.87%
Holdings
NameEquities%Valuation
ASTRAZENECA PHARMA INDIA LIMITED (506820) 18,750,000 75.0% 727,732,688 USD
DIZAL JIANGSU PHARMACEUTICAL CO. LTD. 108,923,023 29.8% 387,144,011 USD
CIRCASSIA GROUP PLC (CIR) 71,059,999 16.9% 31,972,025 USD
ADC THERAPEUTICS SA (ADCT) 4,011,215 5.22% 27,436,711 USD
INNATE PHARMA (IPH) 7,485,500 9.39% 22,613,172 USD
PIERIS PHARMACEUTICALS, INC. (PIRS) 3,584,230 4.97% 6,379,929 USD
ENTASIS THERAPEUTICS HOLDINGS INC. (ETTX) 2,164,855 4.52% 4,719,384 USD
PHASEBIO PHARMACEUTICALS, INC. (PHAS) 3,004,554 6.17% 2,322,520 USD
ARIDIS PHARMACEUTICALS, INC. (ARDS) 884,956 5.00% 1,017,699 USD
Markets and indexes
- Main Market
- FTSE 100 / FTSE 350, FTSE All-Share, FTSE Eurotop 100, Low Carbon 100 Europe, Nasdaq 100, NASDAQ OMX Nordic 120, OMX Nordic 40, OMX Stockholm 30, Stoxx Europe 50, STOXX Europe 600, Stoxx Global 200, Stoxx UK 50
Stock Exchange Codes
- Bloomberg Code :  AZN:LN
- Reuters Code :  AZN.L
- Datastream Code :  
Company contact information
AstraZeneca PLC
Cambridge Biomedical Campus 1 Francis Crick Avenue
CB2 0AA Cambridge, Cambridgeshire

Phone : +44 (0)20 3749 5000
Fax : +44 (0)20 7604 8151
web site : https://www.astrazeneca.com/investor-relations.html
Brand Portfolio
In partnership withAllbrands.markets
More brands of AstraZeneca PLC
Sector Other Pharmaceuticals
1st jan.Capi. (M$)
ASTRAZENECA PLC24.71%202 861
JOHNSON & JOHNSON4.94%472 389
PFIZER, INC.-11.41%293 506
ELI LILLY AND COMPANY17.55%292 291
ROCHE HOLDING AG-14.90%274 360
ABBVIE INC.13.59%271 782
NOVO NORDISK A/S8.27%253 094
MERCK & CO., INC.20.59%233 712
NOVARTIS AG1.71%184 482
BRISTOL-MYERS SQUIBB COMPANY23.24%163 597
AMGEN INC.9.15%131 173
SANOFI11.02%128 238
GSK PLC12.20%110 496
BAYER AG21.79%58 644
DAIICHI SANKYO CO., LTD.16.62%48 182
TAKEDA PHARMACEUTICAL COMPANY LIMITED21.52%43 362
CHUGAI PHARMACEUTICAL CO., LTD-5.52%42 767
JIANGSU HENGRUI MEDICINE CO., LTD.-20.11%39 196
ZHANGZHOU PIENTZEHUANG PHARMACEUTICAL., LTD-19.56%31 825
ASTELLAS PHARMA INC.12.03%28 215
CATALENT, INC.-16.41%19 179